GLAUCOMA 50 EWAP SEPTEMBER 2022 Having a growth mindset throughout one’s career is important, according to Nathan Radcliffe, MD. But there is discernment and a process that affects when to learn new techniques and adopt new technologies. Dr. Radcliffe said when he finished his glaucoma fellowship, he hadn’t performed MIGS at all. Now, he’s adopted all of the newer MIGS options. “The focus of my career surgically is something that I wasn’t trained to do in fellowship. This highlights the value of taking a perpetual look at your career, and I think that if 3 months have gone by and I’m in the operating room and haven’t found something new to incorporate, changed a technique, talked to a colleague Insights on adopting new technologies by Liz Hillman Editorial Co-Director Contact information Okeke: iglaucoma@gmail.com Radcliffe: drradcliffe@gmail.com This article originally appeared in the June 2022 issue of EyeWorld. It has been slightly modified and appears here with permission from the ASCRS Ophthalmic Services Corp. about a better way to do things, I’m slipping behind,” Dr. Radcliffe said. “We’re fortunate to have change and evolution in our treatments. That’s going to help our field and our patients in the long run. I think having a growth mindset approach to adopting new glaucoma procedures is incredibly valuable.” Dr. Radcliffe and Constance Okeke, MD, spoke with EyeWorld about their process and considerations when it comes to bringing in new options that could enhance patient care in their glaucoma practices. EyeWorld: How do you know when to adopt a new technology or technique? What is the onboarding process like? Dr. Radcliffe: I think a lot of the decisions in when to adopt new technology vary from doctor to doctor, and it’s a disposition that may relate more to our personality characteristics. Some are early adopters and have an itch that needs to be scratched in making sure they’ve tried all the available options, and there are some who vary only a little from their residency training throughout their career. It has to do with your attitude toward rocking the boat and trying new things. In glaucoma, I think there is a general feeling that we need innovation because we are so keenly aware that our current treatment options are never µuite sufficient. They get better every year, they get safer every year, but we know we haven’t cured the disease yet, so we want to keep trying new things. For some doctors, the recommendation of a colleague will be very important. … Relationships can go a long way here as well. I think there is a true value that device representatives from the companies provide because they aren’t just there to push products, they help with education, they have training labs, there are tangible benefits that these representatives bring. The other The Durysta implant is inserted into the inferior anterior chamber; a cotton tip is used for stabilization.
RkJQdWJsaXNoZXIy Njk2NTg0